AbbVie unit sues Chinese rival over blood cancer drug

20-06-2023

Muireann Bolger

AbbVie unit sues Chinese rival over blood cancer drug

Ascannio / Shutterstock.com

Both drug treatments inhibit a protein called Bruton’s tyrosine kinase that can trigger cancer | Lawsuit comes in wake of patent grant for disputed drug | New study caused headaches for AbbVie’s subsidiary.


AbbVie, Pharmacyclics, BeiGene, BTK inhibitor, patent infringement, Brukinsa, Imbruvica

More on this story

FTC weighs in on AbbVie antitrust litigation
22-06-2023

LSIPR